In a report released on May 2, Naureen Quibria from Capital One Financial reiterated a Buy rating on Fennec Pharmaceuticals (FENC – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $9.23.
Quibria covers the Healthcare sector, focusing on stocks such as ADC Therapeutics, Fennec Pharmaceuticals, and Carisma Therapeutics. According to TipRanks, Quibria has an average return of -21.0% and a 22.94% success rate on recommended stocks.
Currently, the analyst consensus on Fennec Pharmaceuticals is a Strong Buy with an average price target of $18.67.
The company has a one-year high of $11.92 and a one-year low of $6.30. Currently, Fennec Pharmaceuticals has an average volume of 137K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FENC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fennec Pharmaceuticals (FENC) Company Description:
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
